Novocure (NASDAQ:NVCR) today announced the results of the METIS phase 3 clinical trial in brain metastases from non-small cell lung cancer (NSCLC) will be presented at the 2024 American Society of Clinical Oncology
Novocure's Phase 3 METIS trial results: TTFields therapy, combined with supportive care, significantly prolongs time to intracranial progression for NSCLC brain metastases patients compared to supportive care alone